课题基金 / 基金详情

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS
伊班膦酸钠治疗骨质疏松症 3 年
批准号:
6117775
负责人:
C. CONRAD JOHNSTON
金额:
$1.7万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

C. CONRAD JOHNSTON的其他基金

相似基金

相关文献

中文摘要
翻译
这项为期三年的第三阶段研究的目的是调查 伊班膦酸钠长期治疗原发性高血压的疗效观察 绝经后骨质疏松症的疗效和安全性 使用间歇性静脉治疗新发椎体骨折 骨折作为主要终点。 具体目标是: 确定伊班膦酸盐是否能预防女性骨折和骨质流失 患有绝经后骨质疏松症 为了确定与i.v. 伊班膦酸盐的使用 测定治疗后血液中伊班膦酸盐的含量 并估计药物在血液中停留的时间。
英文摘要
The purpose of this three year phase III study is to investigate the therapeutic effect of ibandronate in the long-term treatment of postmenopausal osteoporosis by evaluating the efficacy and safety of intermittent intravenous treatment using the incidence of new vertebral fractures as the primary endpoint. The specific objectives are: To determine whether Ibandronate prevents fractures and bone loss in women with established postmenopausal osteoporosis. To determine the type of side effects associated with the i.v. administration of Ibandronate. To determine the amount of Ibandronate in the blood following treatment and to estimate how long the drug stays in the blood.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF SEX STEROIDS IN AGE-RELATED BONE LOSS
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
海外基金